3 mayo 2016 año - FDA convened a joint meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee to discuss results from assessments of the extended-release and long- acting (ER/LA) Opioid Analgesics Risk Evaluation and Mitigation Strategies (REMS)
Añadido al timeline:
fecha:
3 mayo 2016 año
Ahora mismo
~ 9 years and 5 months ago